A Preclinical Evaluation of Antimycin A as a Potential Antilung Cancer Stem Cell Agent
Figure 5
Antimycin A suppresses lung tumorigenesis in vivo. (a) Noninvasive bioluminescence imaging was used to monitor the tumor inhibitory effects of AMA in vivo. Mice bearing A549 SP cells were divided into control and AMA groups ( each group). Over time, AMA-treated mice demonstrated suppressed lung tumorigenesis, as demonstrated by lower bioluminescence signals. (b) Quantitative bioluminescence data demonstrate the fold changes in bioluminescence signal over time from both control and AMA groups. (c) Immunohistochemical analysis of tumor biopsies. AMA-treated sections demonstrated weaker staining of β-catenin and NF-κB-p65 compared to those in the sections from control animals. Analysis of EMT markers indicates that AMA-treated sections showed decreased Vimentin and increased E-cadherin as compared to the sections obtained from control mice. *refers to the significant difference observed in the fold change in bioluminescence between control and antimycin A groups. *.
